CL2013000202A1 - Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria. - Google Patents

Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.

Info

Publication number
CL2013000202A1
CL2013000202A1 CL2013000202A CL2013000202A CL2013000202A1 CL 2013000202 A1 CL2013000202 A1 CL 2013000202A1 CL 2013000202 A CL2013000202 A CL 2013000202A CL 2013000202 A CL2013000202 A CL 2013000202A CL 2013000202 A1 CL2013000202 A1 CL 2013000202A1
Authority
CL
Chile
Prior art keywords
activated
antibody against
potentiated form
activated potentiated
histamine
Prior art date
Application number
CL2013000202A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130352/15A external-priority patent/RU2528093C2/ru
Priority claimed from RU2011125992/15A external-priority patent/RU2529783C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of CL2013000202A1 publication Critical patent/CL2013000202A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013000202A 2010-07-21 2013-01-21 Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria. CL2013000202A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130352/15A RU2528093C2 (ru) 2010-07-21 2010-07-21 Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля
RU2011125992/15A RU2529783C2 (ru) 2011-06-24 2011-06-24 Лекарственное средство для лечения патологического синдрома и способ лечения острых и хронических заболеваний дыхательноый системы и синдрома кашля

Publications (1)

Publication Number Publication Date
CL2013000202A1 true CL2013000202A1 (es) 2015-01-16

Family

ID=44899162

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000202A CL2013000202A1 (es) 2010-07-21 2013-01-21 Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.

Country Status (22)

Country Link
US (2) US8795657B2 (OSRAM)
EP (1) EP2595655A2 (OSRAM)
JP (2) JP2013533269A (OSRAM)
CN (1) CN103200964A (OSRAM)
AR (1) AR082313A1 (OSRAM)
AU (1) AU2011281247B2 (OSRAM)
BR (1) BR112013001297A2 (OSRAM)
CA (1) CA2805978C (OSRAM)
CL (1) CL2013000202A1 (OSRAM)
DE (1) DE112011102412T5 (OSRAM)
EA (1) EA029228B1 (OSRAM)
ES (1) ES2425315R1 (OSRAM)
FR (1) FR2962909A1 (OSRAM)
GB (1) GB2496800B (OSRAM)
IT (1) ITTO20110638A1 (OSRAM)
MX (1) MX356678B (OSRAM)
MY (1) MY158522A (OSRAM)
NZ (1) NZ606977A (OSRAM)
PE (1) PE20130387A1 (OSRAM)
PH (1) PH12013500142A1 (OSRAM)
SG (1) SG187579A1 (OSRAM)
WO (1) WO2012010973A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
JP2013532182A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
EA030566B1 (ru) 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
PE20131065A1 (es) * 2010-07-21 2013-09-23 Oleg Iliich Epshtein Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
US20130045237A1 (en) * 2010-08-06 2013-02-21 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
IL125743A (en) 1996-02-12 2003-09-17 Epshtein Oleg Iliich Medicinal preparation containing an active medical substance with homeopathic potentiation
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2103999C1 (ru) 1997-01-31 1998-02-10 Олег Ильич Эпштейн Способ лечения алкоголизма
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2199244C2 (ru) * 2000-10-05 2003-02-27 Самофалова Лариса Александровна Способ получения пищевой муки масличных семян
RU2197266C1 (ru) 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2191602C1 (ru) 2001-06-01 2002-10-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения аллергических и псевдоаллергических реакций
RU2199344C1 (ru) * 2001-12-07 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения синдрома кашля
RU2206338C1 (ru) 2001-12-07 2003-06-20 Эпштейн Олег Ильич Способ лечения синдрома кашля
RU2199345C1 (ru) 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209083C1 (ru) 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения кашля
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
MX2008015621A (es) * 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
SG190594A1 (en) * 2008-04-29 2013-06-28 Gunvant Devichand Oswal A homeopathic formulation
BR112013000842A2 (pt) 2010-07-15 2016-06-07 Oleg Lliich Epshtein composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
NZ606775A (en) 2010-07-15 2015-08-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating genitourinary system disorders
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
SG187037A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
PE20131065A1 (es) * 2010-07-21 2013-09-23 Oleg Iliich Epshtein Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
US20130045237A1 (en) 2010-08-06 2013-02-21 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Also Published As

Publication number Publication date
SG187579A1 (en) 2013-03-28
BR112013001297A2 (pt) 2017-11-21
ITTO20110638A1 (it) 2012-01-22
MX356678B (es) 2018-06-08
CN103200964A (zh) 2013-07-10
ES2425315R1 (es) 2014-09-08
AU2011281247B2 (en) 2015-07-30
PH12013500142A1 (en) 2013-03-11
MY158522A (en) 2016-10-14
JP2013533269A (ja) 2013-08-22
GB2496800B (en) 2018-05-23
GB2496800A (en) 2013-05-22
ES2425315A2 (es) 2013-10-14
MX2013000806A (es) 2013-10-28
WO2012010973A3 (en) 2012-04-26
NZ606977A (en) 2015-08-28
GB201302926D0 (en) 2013-04-03
DE112011102412T5 (de) 2013-07-04
FR2962909A1 (fr) 2012-01-27
US20120225074A1 (en) 2012-09-06
US20150023985A1 (en) 2015-01-22
PE20130387A1 (es) 2013-03-30
AR082313A1 (es) 2012-11-28
AU2011281247A1 (en) 2013-03-14
EP2595655A2 (en) 2013-05-29
US8795657B2 (en) 2014-08-05
JP2016216479A (ja) 2016-12-22
EA029228B1 (ru) 2018-02-28
WO2012010973A2 (en) 2012-01-26
EA201300131A1 (ru) 2013-11-29
CA2805978C (en) 2016-06-28
CA2805978A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
CL2013000202A1 (es) Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
IL260579B (en) Diagnosis, prevention and treatment of joint diseases
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
FIC20200007I1 (fi) Sarolaneeri tai sen farmaseuttisesti hyväksyttävä suola, moksidektiini ja pyranteeliembonaatti
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
IL227298A0 (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
WO2012062925A3 (en) Compounds and methods for treating pain
WO2012007839A3 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
BRPI1010718A2 (pt) sistemas modelo e regimes de tratamento para tratar doença neurológica.
GT201400069A (es) Composiciones farmaceuticas
CL2011001817A1 (es) Forma de dosificacion unitaria solida oral en forma de tableta que comprende un nucleo y un recubrimiento externo, en donde el nucleo comprende alisquireno o a una sal del mismo, y el recubrimiento en un recubrimiento de pelicula, util para el tratamiento de una enfermedad o condicion en una poblacion pediatrica.
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
BR112013031117A2 (pt) scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
WO2013117744A3 (en) Methods of treating fibrosis
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
EP2990040A4 (en) Therapeutic agent for eyeground disease
IL228666A0 (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans